Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C6F14 |
| Molecular Weight | 338.0418 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F
InChI
InChIKey=ZJIJAJXFLBMLCK-UHFFFAOYSA-N
InChI=1S/C6F14/c7-1(8,3(11,12)5(15,16)17)2(9,10)4(13,14)6(18,19)20
| Molecular Formula | C6F14 |
| Molecular Weight | 338.0418 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.ncbi.nlm.nih.gov/books/NBK25382/
Curator's Comment: description was created based on several sources, including:
http://www.ncbi.nlm.nih.gov/books/NBK25382/
Perflexane is a contrast agent for ultrasound Imaging. The mechanism of action of perflexane is an ultrasound contrast activity. Perflexane is a fluorinated hydrocarbon and gaseous substance used as an imaging contrast agent in the echocardiogram. After administration in microsphere form, perflexane increases ultrasound reflectivity of blood. This leads to an improvement of ultrasound signaling. Perflexane-lipid microspheres (AFO150) is a preparation of perfluorocarbon (PFC)-based micro bubbles it was approved by the Food and Drug Administration in 2002 for clinical use in echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. However, AFO150 is not currently available for clinical applications.
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
26.3 ng/mL |
20 μg/kg bw single, intravenous dose: 20 μg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
PERFLEXANE blood | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
11.3 ng × h/mL |
20 μg/kg bw single, intravenous dose: 20 μg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
PERFLEXANE blood | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5.3 h |
20 μg/kg bw single, intravenous dose: 20 μg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
PERFLEXANE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
5.7 h |
20 μg/kg bw single, intravenous dose: 20 μg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered: |
PERFLEXANE blood | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Delivery of water-soluble drugs using acoustically triggered perfluorocarbon double emulsions. | 2010-12 |
|
| Pilot study of vaporization of perfluorohexane during high-frequency oscillatory ventilation in experimental acute lung injury. | 2010-11 |
|
| Effects of perfluorohexane vapor in the treatment of experimental lung injury. | 2010-10 |
|
| Controlling the thickness of hollow polymeric microspheres prepared by electrohydrodynamic atomization. | 2010-08-06 |
|
| Pretreatment with perfluorohexane vapor attenuates fMLP-induced lung injury in isolated perfused rabbit lungs. | 2010-08 |
|
| A new method for the preparation of monoporous hollow microspheres. | 2010-04-06 |
|
| Female scent signals enhance the resistance of male mice to influenza. | 2010-03-01 |
|
| Phospholipid-coated gas bubble engineering: key parameters for size and stability control, as determined by an acoustical method. | 2010-02-02 |
|
| Sonochemical synthesis of liquid-encapsulated lysozyme microspheres. | 2010-02 |
|
| Permeation of a metalworking fluid through a latex glove under field use conditions. | 2010-01 |
|
| Gels from a semifluorinated n-alkane in fluorinated solvents as a probe for intermolecular interactions. | 2009-11-01 |
|
| Perfluorinated compounds in delivering women from south central Vietnam. | 2009-11 |
|
| Reverse water-in-fluorocarbon microemulsions stabilized by new polyhydroxylated nonionic fluorinated surfactants. | 2009-08-18 |
|
| Polyfluoroalkyl chemicals in the serum and milk of breastfeeding women. | 2009-06 |
|
| Systemic perfluorohexane attenuates lung injury induced by lipopolysaccharide in rats: the role of heme oxygenase-1. | 2009-05-19 |
|
| A novel and stable "two-hit" acute lung injury model induced by oleic acid in piglets. | 2009-03-30 |
|
| Environmental hazards and health risk of common liquid perfluoro-n-alkanes, potent greenhouse gases. | 2009-02 |
|
| The multi-vicinal fluoroalkane motif: an examination of 2,3,4,5-tetrafluorohexane stereoisomers. | 2008-09-07 |
|
| Perfluorohexane-loaded macrophages as a novel ultrasound contrast agent: a feasibility study. | 2008-09 |
|
| Structure and depletion at fluorocarbon and hydrocarbon/water liquid/liquid interfaces. | 2008-08-15 |
|
| Leukocyte antibacterial functions are not impaired by perfluorocarbon exposure in vitro. | 2008-07 |
|
| Solvation of halogens in fluorous phases. Experimental and simulation data for F2, Cl2, and Br2 in several fluorinated liquids. | 2008-05-29 |
|
| Influence of collection solvent on permeation of di-n-octyl disulfide through nitrile glove material. | 2008-03-01 |
|
| Exposure of an adult population to perfluorinated substances using duplicate diet portions and biomonitoring data. | 2007-11-15 |
|
| Permeation of a straight oil metalworking fluid through disposable nitrile, chloroprene, vinyl, and latex gloves. | 2007-08-25 |
|
| A study of the formulation design of acoustically active lipospheres as carriers for drug delivery. | 2007-08 |
|
| Oil-in-oil microencapsulation technique with an external perfluorohexane phase. | 2007-06-29 |
|
| Real-time cerebral angiography: sensitivity of a new contrast-specific ultrasound technique. | 2007-04 |
|
| Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells. | 2007-02 |
|
| Effects of vaporized perfluorohexane and partial liquid ventilation on regional distribution of alveolar damage in experimental lung injury. | 2007-02 |
|
| Contrast-enhanced ultrasound as a predictor of treatment efficacy within 2 weeks after transarterial chemoembolization of hepatocellular carcinoma. | 2007-01 |
|
| Positive end-expiratory pressure at minimal respiratory elastance represents the best compromise between mechanical stress and lung aeration in oleic acid induced lung injury. | 2007 |
|
| Rate enhancement of Diels-Alder reactions in aqueous perfluorinated emulsions. | 2006-11-23 |
|
| Raman microspectroscopy/imaging study on phase-vanishing processes of fluorous biphase systems in microchannel-microheater chips. | 2006-10 |
|
| A model for reflectivity enhancement due to surface bound submicrometer particles. | 2006-08 |
|
| Cyclic variation in ultrasonic myocardial integrated backscatter is due to phasic changes in the number of patent myocardial microvessels. | 2006-08 |
|
| Effects of IMAGENT on pulmonary hemodynamics and gas exchange in dogs. | 2006-06 |
|
| Angiogenesis: noninvasive quantitative assessment with contrast-enhanced functional US in murine model. | 2006-06 |
|
| Polymeric nano/microcapsules of liquid perfluorocarbons for ultrasonic imaging: physical characterization. | 2006-04-25 |
|
| Comparative effects of vaporized perfluorohexane and partial liquid ventilation in oleic acid-induced lung injury. | 2006-02 |
|
| Characterization of phospholipid+semifluorinated alkane vesicle system. | 2006-01-15 |
|
| Investigating perfluorohexane particles with high-frequency ultrasound. | 2006-01 |
|
| Effects of perfluorohexan vapor on gas exchange, respiratory mechanics, and lung histology in pigs with lung injury after endotoxin infusion. | 2005-09 |
|
| Transcranial ultrasound angiography (T USA): a new approach for contrast specific imaging of intracranial arteries. | 2005-08 |
|
| Aging mechanisms of perfluorocarbon emulsions using image analysis. | 2005-06-01 |
|
| Perfluorohexane vapor has only minor effects on spatial pulmonary blood flow distribution in isolated rabbit lungs. | 2005-04 |
|
| Comparison of different inhalational perfluorocarbons in a rabbit model of acute lung injury. | 2005-03-05 |
|
| Vaporized perfluorohexane attenuates ventilator-induced lung injury in isolated, perfused rabbit lungs. | 2005-03 |
|
| Effect of oxygenated perfluorocarbons on isolated rat pancreatic islets in culture. | 2005 |
|
| Liquid crystalline behavior of a semifluorinated oligomer. | 2004-12-08 |
Sample Use Guides
The recommended dose is 0.00625 mL/kg (0.125 mg/kg) administered as a single intravenous bolus over a period of not less than 10 seconds and immediately followed by a saline flush. Imagent (The active moiety, the microsphere, comprises two critical components: perflexane, the gaseous component, and DMPC, the lipid membrane component) must be used within 30 minutes of reconstitution.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:15:39 GMT 2025
by
admin
on
Mon Mar 31 18:15:39 GMT 2025
|
| Record UNII |
FX3WJ41CMX
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NDF-RT |
N0000010259
Created by
admin on Mon Mar 31 18:15:39 GMT 2025 , Edited by admin on Mon Mar 31 18:15:39 GMT 2025
|
||
|
CFR |
21 CFR 173.342
Created by
admin on Mon Mar 31 18:15:39 GMT 2025 , Edited by admin on Mon Mar 31 18:15:39 GMT 2025
|
||
|
NDF-RT |
N0000175864
Created by
admin on Mon Mar 31 18:15:39 GMT 2025 , Edited by admin on Mon Mar 31 18:15:39 GMT 2025
|
||
|
NCI_THESAURUS |
C1937
Created by
admin on Mon Mar 31 18:15:39 GMT 2025 , Edited by admin on Mon Mar 31 18:15:39 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C078626
Created by
admin on Mon Mar 31 18:15:39 GMT 2025 , Edited by admin on Mon Mar 31 18:15:39 GMT 2025
|
PRIMARY | |||
|
39427
Created by
admin on Mon Mar 31 18:15:39 GMT 2025 , Edited by admin on Mon Mar 31 18:15:39 GMT 2025
|
PRIMARY | |||
|
1540828
Created by
admin on Mon Mar 31 18:15:39 GMT 2025 , Edited by admin on Mon Mar 31 18:15:39 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB33239
Created by
admin on Mon Mar 31 18:15:39 GMT 2025 , Edited by admin on Mon Mar 31 18:15:39 GMT 2025
|
PRIMARY | |||
|
FX3WJ41CMX
Created by
admin on Mon Mar 31 18:15:39 GMT 2025 , Edited by admin on Mon Mar 31 18:15:39 GMT 2025
|
PRIMARY | |||
|
PERFLUOROHEXANE
Created by
admin on Mon Mar 31 18:15:39 GMT 2025 , Edited by admin on Mon Mar 31 18:15:39 GMT 2025
|
PRIMARY | |||
|
100000126369
Created by
admin on Mon Mar 31 18:15:39 GMT 2025 , Edited by admin on Mon Mar 31 18:15:39 GMT 2025
|
PRIMARY | |||
|
9639
Created by
admin on Mon Mar 31 18:15:39 GMT 2025 , Edited by admin on Mon Mar 31 18:15:39 GMT 2025
|
PRIMARY | |||
|
FX3WJ41CMX
Created by
admin on Mon Mar 31 18:15:39 GMT 2025 , Edited by admin on Mon Mar 31 18:15:39 GMT 2025
|
PRIMARY | |||
|
DB09531
Created by
admin on Mon Mar 31 18:15:39 GMT 2025 , Edited by admin on Mon Mar 31 18:15:39 GMT 2025
|
PRIMARY | |||
|
m8541
Created by
admin on Mon Mar 31 18:15:39 GMT 2025 , Edited by admin on Mon Mar 31 18:15:39 GMT 2025
|
PRIMARY | Merck Index | ||
|
7871
Created by
admin on Mon Mar 31 18:15:39 GMT 2025 , Edited by admin on Mon Mar 31 18:15:39 GMT 2025
|
PRIMARY | |||
|
355-42-0
Created by
admin on Mon Mar 31 18:15:39 GMT 2025 , Edited by admin on Mon Mar 31 18:15:39 GMT 2025
|
PRIMARY | |||
|
7917
Created by
admin on Mon Mar 31 18:15:39 GMT 2025 , Edited by admin on Mon Mar 31 18:15:39 GMT 2025
|
PRIMARY | |||
|
DTXSID7046548
Created by
admin on Mon Mar 31 18:15:39 GMT 2025 , Edited by admin on Mon Mar 31 18:15:39 GMT 2025
|
PRIMARY | |||
|
CHEMBL1200607
Created by
admin on Mon Mar 31 18:15:39 GMT 2025 , Edited by admin on Mon Mar 31 18:15:39 GMT 2025
|
PRIMARY | |||
|
KK-122
Created by
admin on Mon Mar 31 18:15:39 GMT 2025 , Edited by admin on Mon Mar 31 18:15:39 GMT 2025
|
PRIMARY | |||
|
3429
Created by
admin on Mon Mar 31 18:15:39 GMT 2025 , Edited by admin on Mon Mar 31 18:15:39 GMT 2025
|
PRIMARY | |||
|
206-585-0
Created by
admin on Mon Mar 31 18:15:39 GMT 2025 , Edited by admin on Mon Mar 31 18:15:39 GMT 2025
|
PRIMARY | |||
|
C47663
Created by
admin on Mon Mar 31 18:15:39 GMT 2025 , Edited by admin on Mon Mar 31 18:15:39 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
